IRVINE, Calif., Jan. 17, 2017 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, has received CE Mark for its HemoSphere advanced monitoring platform, which provides greater clarity on a patient’s hemodynamic status to enable clinicians to make timely, potentially life-saving decisions.
“The HemoSphere advanced monitor enables simplified visual clinical support, which is particularly important in the care of our most complex critically ill patients,” said Prof. Marco Maggiorini, M.D., head of the medical ICU at University Hospital Zurich. “Clinicians can choose the clinical support screens that best suit their needs, enabling proactive decisions on behalf of their patients.”
Building on Edwards’ more than 50 years of experience in providing clinicians with tools to help advance patient care, the HemoSphere advanced monitor represents the next generation of hemodynamic monitoring. The advanced monitor incorporates high-quality visual clinical support screens and an intuitive touchscreen. The platform is wireless-enabled and provides adaptive modularity, which means that clinical teams can adapt the system to meet the needs of their care environment. The HemoSphere advanced monitor is currently compatible with the Edwards Swan-Ganz pulmonary artery catheter and Oximetry catheters.
Ad Statistics
Times Displayed: 7549
Times Visited: 112 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
“The HemoSphere advanced monitor provides a strong foundation for Edwards to continue to innovate and advance new hemodynamic solutions, now and in the future,” said Catherine M. Szyman, Edwards’ corporate vice president, critical care. “The design of this monitoring platform enables clinicians to treat their patients using more customized, informative and advanced parameters.”
Hemodynamic monitoring is the measurement of blood circulation and cardiac function that allows clinicians to evaluate whether enough oxygen is being delivered to a patient’s organs and tissues. Healthcare providers use this information to detect changes or problems in a patient's health, which allows for more informed, immediate treatment decisions.
The HemoSphere advanced monitoring platform is not cleared for commercial use in the U.S.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.edwards.com and follow us on Twitter @EdwardsLifesci.
Edwards, Edwards Lifesciences, the stylized E logo, HemoSphere, Swan and Swan-Ganz are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
